CRVL vs. NVO

Last updated Apr 2, 2026

Compare and contrast key facts about CorVel Corporation (CRVL) and Novo Nordisk A/S (NVO).

Performance

CRVL vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CorVel Corporation (CRVL) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

CRVL vs. NVO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CRVL CorVel Corporation	-20.79%	-39.18%	35.02%	70.10%	-30.13%	96.23%	21.34%	41.54%	16.67%	44.54%
NVO Novo Nordisk A/S	-25.80%	-39.22%	-15.93%	54.84%	22.66%	63.52%	23.33%	28.70%	-12.98%	52.92%

Fundamentals

Market Cap CRVL : $2.76B NVO : $162.26B
EPS CRVL : $2.04 NVO : $22.15
PE Ratio CRVL : 26.23 NVO : 1.65
PEG Ratio CRVL : 1.19 NVO : 0.07
PS Ratio CRVL : 2.95 NVO : 0.55
PB Ratio CRVL : 7.36 NVO : 0.84
Total Revenue (TTM) CRVL : $941.49M NVO : $297.20B
Gross Profit (TTM) CRVL : $227.82M NVO : $240.66B
EBITDA (TTM) CRVL : $167.61M NVO : $153.18B

Returns By Period

In the year-to-date period, CRVL achieves a -20.79% return, which is significantly higher than NVO's -25.80% return. Over the past 10 years, CRVL has outperformed NVO with an annualized return of 14.59%, while NVO has yielded a comparatively lower 5.04% annualized return.

CRVL

• 1D: -1.92%
• 1M: 2.25%
• YTD: -20.79%
• 6M: -27.14%
• 1Y: -52.74%
• 3Y*: -5.46%
• 5Y*: 8.98%
• 10Y*: 14.59%

NVO

• 1D: -0.73%
• 1M: -0.01%
• YTD: -25.80%
• 6M: -36.19%
• 1Y: -43.88%
• 3Y*: -20.88%
• 5Y*: 3.69%
• 10Y*: 5.04%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CRVL vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRVL

CRVL Risk / Return Rank: 5
CRVL Sharpe Ratio Rank: 1
CRVL Sortino Ratio Rank: 2
CRVL Omega Ratio Rank: 1
CRVL Calmar Ratio Rank: 10
CRVL Martin Ratio Rank: 9

NVO

NVO Risk / Return Rank: 10
NVO Sharpe Ratio Rank: 8
NVO Sortino Ratio Rank: 11
NVO Omega Ratio Rank: 10
NVO Calmar Ratio Rank: 11
NVO Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRVL vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CorVel Corporation (CRVL) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CRVL	NVO	Difference
Sharpe ratio Return per unit of total volatility	-1.35	-0.81	-0.54
Sortino ratio Return per unit of downside risk	-1.96	-0.99	-0.96
Omega ratio Gain probability vs. loss probability	0.70	0.86	-0.16
Calmar ratio Return relative to maximum drawdown	-0.85	-0.82	-0.03
Martin ratio Return relative to average drawdown	-1.49	-1.41	-0.07
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CRVL vs. NVO - Sharpe Ratio Comparison

The current CRVL Sharpe Ratio is -1.35, which is lower than the NVO Sharpe Ratio of -0.81. The chart below compares the historical Sharpe Ratios of CRVL and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CRVL	NVO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-1.35	-0.81	-0.54
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.28	0.10	+0.18
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.43	0.16	+0.27
Sharpe Ratio (All Time) Calculated using the full available price history	0.37	0.46	-0.09

Correlation

The correlation between CRVL and NVO is 0.15, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CRVL vs. NVO - Dividend Comparison

CRVL has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 4.94%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CRVL CorVel Corporation	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVO Novo Nordisk A/S	4.94%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%

Drawdowns

CRVL vs. NVO - Drawdown Comparison

The maximum CRVL drawdown since its inception was -67.12%, smaller than the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for CRVL and NVO.

Drawdown Indicators

	CRVL	NVO	Difference
Max Drawdown Largest peak-to-trough decline	-67.12%	-74.70%	+7.58%
Max Drawdown (1Y) Largest decline over 1 year	-61.23%	-55.03%	-6.20%
Max Drawdown (5Y) Largest decline over 5 years	-64.19%	-74.70%	+10.51%
Max Drawdown (10Y) Largest decline over 10 years	-64.19%	-74.70%	+10.51%
Current Drawdown Current decline from peak	-58.27%	-73.49%	+15.22%
Average Drawdown Average peak-to-trough decline	-20.18%	-17.56%	-2.62%
Ulcer Index Depth and duration of drawdowns from previous peaks	35.10%	31.83%	+3.27%

Volatility

CRVL vs. NVO - Volatility Comparison

The current volatility for CorVel Corporation (CRVL) is 8.32%, while Novo Nordisk A/S (NVO) has a volatility of 9.39%. This indicates that CRVL experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CRVL	NVO	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.32%	9.39%	-1.07%
Volatility (6M) Calculated over the trailing 6-month period	36.72%	38.79%	-2.07%
Volatility (1Y) Calculated over the trailing 1-year period	39.20%	54.16%	-14.96%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	32.66%	37.82%	-5.16%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	34.26%	32.28%	+1.98%

Financials

CRVL vs. NVO - Profitability Comparison

The chart below illustrates the profitability comparison between CorVel Corporation and Novo Nordisk A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

CRVL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, CorVel Corporation reported a gross profit of 54.92M and revenue of 235.63M. Therefore, the gross margin over that period was 23.3%.

NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a gross profit of 54.38B and revenue of 67.28B. Therefore, the gross margin over that period was 80.8%.

CRVL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, CorVel Corporation reported an operating income of 32.23M and revenue of 235.63M, resulting in an operating margin of 13.7%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported an operating income of 27.12B and revenue of 67.28B, resulting in an operating margin of 40.3%.

CRVL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, CorVel Corporation reported a net income of 24.17M and revenue of 235.63M, resulting in a net margin of 10.3%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a net income of 22.96B and revenue of 67.28B, resulting in a net margin of 34.1%.